GBA's "2021 Stock Phantasma"

A hedge fund did not disclose it's positions to SEC>> Is that possible. Family office....
SWAPS what? family office? What?

CohBar completes enrollment in Phase 1b clinical trial for CB4211 09:02 CWBR CohBar announced the completion of enrollment in the Phase 1b stage of the CB4211 clinical study for nonalcoholic steatohepatitis and obesity. The company currently expects topline data at the end of Q2 based on projected timing of the last subject visit and other factors. The company plans to announce the completion of the last subject visit, which is currently anticipated in April.
 
HUGE WINDS TODAY IN CT!!!

I don't get this when I get up here everyone is on 7th heaven talking non stop about the weather and since I've been here it's been pouring rain and freezing with winds above 50 MPH and snow maybe thurs!!!! Common" This is my Spring Break!

Oscar Health initiated with a Buy at BofA 08:57 OSCR BofA analyst Kevin Fischbeck initiated coverage of Oscar Health with a Buy rating and $39 price target. Oscar Health has good visibility into growing revenues 30%-40%+ per year organically for the next several years, and achieve Insurance segment profitability by 2023, Fischbeck tells investors in a research note. The analyst adds that there is plenty of white space left for geographic expansion to continue and that Oscar Health is also poised to benefit from legislative tailwinds.
 
Oscar Health initiated with an Overweight at Morgan Stanley »

This must be post IPO roll out... 2 firms. Wouldn't put much in it but i do like Oscar they charge a freakin ton.
 
I'm going to make one of my Stalin- like calls to the Hedge Fund... and in a very broad way say-

More Health. I'm stuck on the repressed surgeries angle and all the medical backlog I think this is a huge opportunity and I don't know exactly how to play it- One Med? Oscar?
 
--Walgreens Boots Alliance price target raised to $53 from $41 at Cowen »

Got a hunch Rkt is going to take pff again.
Rocket Companies call volume above normal and directionally bullish
 
name I played in the old days) One of the 1st On Demand stks
SeaChange secures multi-million-dollar contract with broadband service in U.S. 07:33 SEAC

Morgan Stanley ups Johnson Controls ahead of commercial buildings upgrades 07:30 JCI, CARR As previously reported, Morgan Stanley analyst Joshua Pokrzywinski upgraded Johnson Controls (JCI) to Overweight from Equal Weight with a price target of $73, up from $52. Driven by shorter paybacks, sustainability efforts, and legislation, Pokrzywinski foresees a coming commercial buildings upgrade "supercycle" and he thinks the market is underestimating how much commercial building retrofits can accelerate growth for Johnson Controls and Carrier Global (CARR). Given technology, ESG awareness, an aging installed base, post-COVID changes, and funding support, Pokrzywinski sees growth in replacement and retrofit activity in commercial buildings in the U.S. and Europe accelerating from a low-single-digit percentage to an 8% compound annual growth rate over the next 15 years, he tells investors in a research note.
 
Olin price target raised to $55 from $37 at Alembic Global » 07:18 OLN

Bluebird Bio approval could improve sentiment on shares, says Mizuho 07:14 BLUE Mizuho analyst Difei Yang raised the firm's price target on Bluebird Bio to $70 from $69 and reiterates a Buy rating on the shares after the FDA approved Abecma. This represents an "important milestone" for Bluebird given recent setbacks surrounding the company's gene therapy programs, Yang tells investors in a research note. The analyst believes the approval "could give renewed comfort to investors and improve sentiment around the stock."

Upland Software assumed with an Outperform at Credit Suisse 06:28 UPLD Credit Suisse analyst Yaoxian Chew assumed coverage of Upland Software with an Outperform rating and $58 price target. The analyst made no change to the rating or price target. Show

WeWork has cut two-thirds of its staff since 2019, Business Insider reports

This WeWork kind of becomes interesting having sat out the Pandemic and now obviously leaner could they specialize in Covid protected sort of spaces and thrive ....
 
Nomura announces 'significant loss' arising from transactions with U.S. client » 05:48 NMR

I don't like this... What of Nomura has to sell everything this cold cascade...
 
You get these weird foreign companies that get mentioned alot. I mean alot.. There Heidenberg cement or something and there's this Taylor Wimpey upgraded to Overweight from Neutral at JPMorgan » TWODF ... Mr Wimpey shows up a lot he might be a supermarket? I have to double check.
 
You must log in or register to reply here.
Back
Top